 Connection
Peter Kabos to Heterografts
This is a "connection" page, showing publications Peter Kabos has written about Heterografts.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.143 |
|
|
|
-
Dwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CA. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer. Br J Cancer. 2021 01; 124(1):217-227.
Score: 0.043
-
Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, Harrell JC, Kabos P, Sartorius CA. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020 06 23; 22(1):68.
Score: 0.042
-
Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016 12; 35(4):547-573.
Score: 0.033
-
Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res. 2012 Jul 05; 14(4):R100.
Score: 0.024
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|